Cognition Therapeutics reported financial results for the quarter ended June 30, 2026, posting a net loss of $3.9 million, or $(0.04) per share, compared to a $6.7 million loss in the prior year period. Research and development expenses decreased to $5.1 million from $11.5 million due to lower trial activities, while general and administrative expenses rose slightly to $2.6 million. The company held approximately $34.8 million in cash as of June 30, 2026, with sufficient funds to support operations through the fourth quarter of 2027. Clinically, Cognition Therapeutics received a Notice of Allowance for a composition of matter patent extending protection for zervimesine through 2045 and held FDA discussions regarding the design of a Phase 3 trial for dementia with Lewy bodies psychosis, targeting initiation in mid-2027. The company is a clinical-stage biopharmaceutical firm developing therapies for neurodegenerative diseases.

Cognition Therapeutics, Inc. announced on June 24, 2026, that it received written feedback from the U.S. Food and Drug Administration (FDA) following a meeting held in May 2026. The company is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.